Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
置換アミド類
Document Type and Number:
Japanese Patent JP3813152
Kind Code:
B2
Abstract:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Inventors:
William Kay, Hugman
Lin, Linus S
Shere, Siurenik Kay
Gtaikonda, Ravindra N
Qi, Hong Bo
Linda El, Jiang
Liu pin
Armstrong, Helen M
The Ayeers Peas
Lanza, Thomas The Ray, The Uniya
Application Number:
JP2003575901A
Publication Date:
August 23, 2006
Filing Date:
March 07, 2003
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
MERCK & COMPANY INCOPORATED
International Classes:
C07D213/56; A61K31/165; A61K31/27; A61K31/40; A61K31/4015; A61K31/403; A61K31/405; A61K31/415; A61K31/4192; A61K31/4196; A61K31/42; A61K31/423; A61K31/426; A61K31/428; A61K31/437; A61K31/44; A61K31/4402; A61K31/4409; A61K31/4436; A61K31/445; A61K31/4453; A61K31/4545; A61K31/4709; A61K31/496; A61K31/50; A61K31/501; A61K31/505; A61K31/5377; A61K31/553; A61P1/04; A61P1/10; A61P1/16; A61P3/04; A61P3/06; A61P3/10; A61P5/24; A61P9/04; A61P9/06; A61P9/10; A61P9/12; A61P9/14; A61P11/06; A61P13/12; A61P15/00; A61P15/10; A61P17/00; A61P19/02; A61P19/06; A61P25/00; A61P25/06; A61P25/08; A61P25/16; A61P25/18; C07C233/12; C07C233/13; C07C235/06; C07C235/18; C07C235/20; C07C235/34; C07C235/74; C07C235/78; C07C237/06; C07C255/55; C07C255/60; C07C271/14; C07C271/22; C07C275/30; C07C311/03; C07C323/41; C07D207/27; C07D209/08; C07D209/34; C07D209/52; C07D209/94; C07D211/34; C07D213/36; C07D213/40; C07D213/61; C07D213/64; C07D213/65; C07D213/68; C07D213/89; C07D215/06; C07D231/12; C07D233/36; C07D233/70; C07D233/80; C07D237/14; C07D237/28; C07D237/32; C07D239/34; C07D249/04; C07D249/08; C07D249/12; C07D249/18; C07D261/08; C07D261/20; C07D263/58; C07D267/14; C07D277/20; C07D277/30; C07D277/36; C07D277/64; C07D277/74; C07D295/12; C07D295/13; C07D295/14; C07D295/15; C07D401/12; C07D409/12; C07D413/12; C07D471/04; C07D513/04; C07D521/00; A61P9/00; A61P15/08; A61P25/22; A61P25/24; A61P25/28; A61P25/30; A61P25/32; A61P25/34; A61P25/36; A61P29/00; A61P35/00; A61P35/02; A61P43/00
Domestic Patent References:
JP2000513025A
JP3176469A
JP1156957A
JP9505601A
Foreign References:
WO1995011880A1
WO1995023150A1
WO2001087849A1
WO1999037667A1
Other References:
JACS,1998年,120,10555-10556
J.Am.Chem.Soc.,1956年,78,6123-7
J.Am.Chem.Soc.,1999年,121,2974-2986
Tetrahedron Letters,1997年,Vol.38, No.18, pp3155-3158
J. Lipid Mediators Cell Signalling,15, 1996, pp161-173
J.Am.Chem.Soc., 1996, 118, pp2507-2508
Tetrahedron, Vol.44, No.10, pp2821-2833,1988
Tetrahedron Letters, Vol.27, No.31, pp3639-3642,1986
J.Am.Chem.Soc., 1957, 79, pp734-41
J.Chem.Soc.,Perkin Trans.1, 2000, 1461-1466
Helvetica Chimica Acta, 1988, 81(12), pp2141-2156
Helvetica Chimica Acta, 1988, 81(11), pp2093-2126
J.Chem.Soc.,Perkin Trans.1, 1998, 521-528
J.Chem.Soc.,Perkin Trans.1, 1998, 1459
J.Chem.Soc.,Perkin Trans.1, 1995, 1-2
Journal of the Brazilian Chemical Society, 2001, Vol.12, No.5, pp652-660
Attorney, Agent or Firm:
Yoshio Kawaguchi
Akio Ichiiri
Makoto Ono
Katsuma Osaki
Mitsuaki Tsubokura